Last ¥1,542 JPY
Change Today -38.00 / -2.41%
Volume 35.3K
4573 On Other Exchanges
Symbol
Exchange
Tokyo
As of 12:56 AM 01/29/15 All times are local (Market data is delayed by at least 15 minutes).

r-tech ueno ltd (4573) Snapshot

Open
¥1,578
Previous Close
¥1,580
Day High
¥1,578
Day Low
¥1,540
52 Week High
10/24/14 - ¥1,860
52 Week Low
05/21/14 - ¥945.00
Market Cap
29.8B
Average Volume 10 Days
33.0K
EPS TTM
¥45.86
Shares Outstanding
19.3M
EX-Date
03/27/15
P/E TM
33.6x
Dividend
¥25.00
Dividend Yield
1.62%
Current Stock Chart for R-TECH UENO LTD (4573)

Related News

No related news articles were found.

r-tech ueno ltd (4573) Related Businessweek News

No Related Businessweek News Found

r-tech ueno ltd (4573) Details

R-Tech Ueno, Ltd. is engaged in the research, development, manufacture, and sale of pharmaceutical products for the treatment of ophthalmology and dermatology worldwide. The company offers Rescula eye drops to treat glaucoma and ocular hypertension. Its product pipeline comprises Rescula/UF-021, which is in Phase IIb clinical trials to treat retinitis pigmentosa; RU-101 which is in Phase IIa clinical trials for the treatment of dry eye; and RK-023 that is in Phase IIa clinical trials to treat alopecia, as well as in Phase I clinical trials to treat hypotrichosis of the eyelashes. The company is also developing RTU-007 for treating diabetic cataract and retinopathy, and age-related macula degeneration; RTU-1096 for the treatment of atopic dermatitis, contact dermatitis, psoriasis, and diabetic neuropathy. In addition, it offers R and D assistance services, including development of synthetic methods; contract manufacturing of pharmaceuticals; characterization studies; formulation studies; and quality tests and stability tests for drug substances and drug products. Further, the company is engaged in contract manufacturing of injections, eye drops, liquid drugs, liquid-filled hard capsules, solid formulations, and ointments. R-Tech Ueno, Ltd. was founded in 1989 and is headquartered in Tokyo, Japan.

75 Employees
Last Reported Date: 06/25/14
Founded in 1989

r-tech ueno ltd (4573) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

r-tech ueno ltd (4573) Key Developments

R-Tech Ueno, Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2014; Provides Earnings Guidance for the Nine Months of 2015

R-Tech Ueno, Ltd. reported earnings results for the second quarter and six months ended September 30, 2014. For the quarter, the company reported sales of JPY 1,581 million compared to JPY 1,275 million a year ago. Operating profit was JPY 272 million compared to JPY 256 million a year ago. Recurring profit was JPY 326 million compared to JPY 253 million a year ago. Net profit was JPY 241 million compared to JPY 181 million a year ago. For the six months period, the company reported sales of JPY 2,728 million compared to JPY 2,794 million a year ago. Operating profit was JPY 411 million compared to JPY 713 million a year ago. Recurring profit was JPY 462 million compared to JPY 756 million a year ago. Net profit was JPY 356 million compared to JPY 533 million a year ago. The company provided earnings guidance for the nine months of 2015. The company expects prospective sales of JPY 5,763 million, operating profit of JPY 1,431 million, recurring profit of JPY 1,434 million and net profit of JPY 1,003 million, while prospective operating profit margin 24.8% and gross profit margin 65.5%.

R-Tech Ueno Received Orphan Drug Designation for Unoprostone Isopropyl for the Treatment of Retinitis Pigmentosa from MHLW

R-Tech Ueno, Ltd. announced that the company have officially received the Orphan Drug Designation from the Ministry of Health, Labour and Welfare (MHLW) for Unoprostone Isopropyl (Unoprostone) (development code: UF-021) for the treatment of retinitis pigmentosa. Drugs and biologics with orphan drug designation in Japan are defined as those intended for the safe and effective treatment, diagnosis or prevention of rare diseases/disorders that affect fewer than 50,000 patients (maximal incidence of 4 per 10,000), with incentives for sponsors to develop orphan products such as priority review of New Drug Applications (NDAs) by the Pharmaceuticals and Medical Devices Agency (PMDA), and grant funding for sponsors. The company are developing a therapeutic agent for treatment of retinitis pigmentosa with unoprostone as the main ingredient and are conducting a phase 3 clinical trial of the ophthalmic solution with unoprostone (development code: UF-021) as the main ingredient. A phase 2 clinical trial indicated that the number of patients whose retina sensitivity in the central retina deteriorated was reduced. The development of retinitis pigmentosa treatment by unoprostone in Japan has support from government and was adopted in the Adaptable and Seamless Technology Program through Target-Driven R&D (A-STEP) as "Full-scale R&D Stage - Practical Application Type (Contract Development)" by the Japan Science and Technology Agency.

R-Tech Ueno, Ltd. Announces Non-Consolidated Earnings Results for the Second Quarter and First Half Ended September 30, 2014; Provides Earnings Guidance for the Fiscal Year Ending March 31, 2015; Provides Year End Dividend Guidance for the Fiscal Year Ending March 31, 2015

R-Tech Ueno, Ltd. announced non-consolidated earnings results for the second quarter and first half ended September 30, 2014. For the quarter, net sales were ¥1,581 million, compared to ¥1,275 million a year ago. Operating income was ¥272 million, compared to ¥256 million a year ago. Net income was ¥241 million, compared to ¥181 million a year ago. For the first half, net sales were ¥2,728 million, compared to ¥1,275 million a year ago. Operating income was ¥411 million, compared to ¥713 million a year ago. Net income was ¥356 million or ¥18.36 per diluted share, compared to ¥533 million or ¥27.43 per diluted share a year ago. For the fiscal year ending March 31, 2015, the company expects net sales of ¥5,763 million, operating income of ¥1,431 million, net income of ¥1,003 million or ¥52.01 per share. For the fiscal year 2015, the company expects year end dividend of ¥25 per share.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4573:JP ¥1,542.00 JPY -38.00

4573 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4573.
View Industry Companies
 

Industry Analysis

4573

Industry Average

Valuation 4573 Industry Range
Price/Earnings 31.5x
Price/Sales 5.0x
Price/Book 3.1x
Price/Cash Flow 30.8x
TEV/Sales 3.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact R-TECH UENO LTD, please visit www.rtechueno.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.